Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo

Translational Research

Volumn 152, Issue 5, 2008, Pages 203-212

  Jasinski, Piotr ^a   Zwolak, Pawel ^a   Terai, Kaoru ^a   Dudek, Arkadiusz Z ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MT 477; PROTEIN KINASE C; QUINOLINE DERIVATIVE; RAS PROTEIN; THIOPYRANO[2,3 C]QUINOLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL INVASION; CELL MIGRATION; CELL STRAIN A549; CELL STRAIN H226; CELL STRAIN PACA 2; CELL STRUCTURE; CONTROLLED STUDY; CYTOSKELETON; DRUG EFFICACY; FILOPODIA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG FIBROBLAST; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; XENOGRAFT;

EID: 57649102485     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2008.09.001     Document Type: Article

References (23)

1. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3 (2003) 11-22
2. Luo D., Liu Q.F., Gove C., Naomov N., Su J.J., and Williams R. Analysis of N-ras gene mutation and p53 gene expression in human hepatocellular carcinomas. World J Gastroenterol 4 (1998) 97-99
3. Li D., and Jiao L. Molecular epidemiology of pancreatic cancer. Int J Gastrointest Cancer 33 (2003) 3-14
4. Sugio K., Kishimoto Y., Virmani A.K., Hung J.Y., and Gazdar A.F. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 54 (1994) 5811-5815
5. Cooper C.A., Carby F.A., Bubb V.J., Lamb D., Kerr K.M., and Wyllie A.H. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. J Path 181 (1997) 401-404
6. Rodenhuis S., van de Wetering M.L., Mooi W.J., Evers S.G., van Zandwijk N., and Bos J.L. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Eng J Med 317 (1987) 929-935
7. Okudela K., Hayashi H., Ito T., Yazawa T., Suzuki T., Nakane Y., et al. K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma. Am J Path 164 (2004) 91-100
8. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res 49 (1989) 4682-4689
9. Campbell S.L., Khosravi-Far R., Rossman K.L., Clark G.J., and Der C.J. Increasing complexity of Ras signaling. Oncogene 17 (1998) 1395-1413
10. Ridley A.J., and Hall A. Signal transduction pathways regulating Rho-mediated stress fibre formation: requirement for a tyrosine kinase. EMBO J 13 (1994) 2600-2610
11. Aspenstrom P., Ruusala A., and Pacholsky D. Taking Rho GTPases to the next level: the cellular functions of atypical Rho GTPases. Exp Cell Res 313 (2007) 3673-3679
12. Goldberg L., and Kloog Y. A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res 66 (2006) 11709-11717
13. Azios N.G., and Dharmawardhane S.F. Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells. Neoplasia 7 (2005) 128-140
14. Ying H., Biroc S.L., Li W.W., Alicke B., Xuan J.-A., Pagila R., et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 5 (2006) 2158-2164
15. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., et al. Cell migration: Integrating signals from front to back. Science 302 (2003) 1704-1709
16. Zundelevich A., Elad-Sfadia G., Haklai R., and Kloog Y. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther 6 (2007) 1765-1773
17. Dudek A.Z., Zwolak P., Jasinski P., Terai K., Gallus N.J., Ericson M.E., et al. Protein kinase C-beta inhibitor enzastaurin (LY317615. HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Invest New Drugs 26 (2008) 13-24
18. Galvez J., Garcia-Domenech R., de Julian-Ortiz J.V., and Soler R. Topological approach to drug design. J Chem Inf Comput Sci 35 (1995) 272-284
19. Jasinski P., Welsh B., Galvez J., Land D., Zwolak P., Ghandi L., et al. A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines. Invest New Drugs 26 (2008) 223-232
20. Llompart J, Galvez J, Pal K. 2006 Inventors. U.S. Patent 20060014770.
21. Azios N.G., Krishnamoorthy L., Harris M., Cubano L.A., Cammer M., and Dharmawardhane S.F. Estrogen and resveratrol regulate Rac and Cdc42 signaling to the actin cytoskeleton of metastatic breast cancer cells. Neoplasia 9 (2007) 147-158
22. Lin M., and van Golen K.L. Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res Treat 84 (2004) 49-60
23. Jaffe A.B., and Hall A. Rho GTPases: Biochemistry and biology. Annu Rev Cell Dev Biol 21 (2005) 247-269